DOI QR코드

DOI QR Code

서울 3차 의료기관에서 분리한 헬리코박터 파일로리 항생제 내성률 변화

Changes in the Antibiotic Resistance Rates of Helicobacter pylori Strains Isolated in Tertiary Medical Institutions in Seoul

  • 최원정 (금강아산병원 내과) ;
  • 도기원 (금강아산병원 내과) ;
  • 이진혁 (울산대학교 의과대학 서울아산병원 내과)
  • Choi, Won Jung (Department of Internal Medicine, Geumgang Asan Hospital) ;
  • Do, Gi Won (Department of Internal Medicine, Geumgang Asan Hospital) ;
  • Lee, Gin Hyug (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2013.01.21
  • 심사 : 2013.06.18
  • 발행 : 2014.03.01

초록

목적: 헬리코박터 제균의 성공여부를 결정하는 주요 요소는 환자의 순응도와 항생제에 대한 내성 유무이다. 본 논문에서는 현재 쓰고 있는 제균요법의 유효성을 검증하는 기초자료로서 2004년부터 2010년까지 서울아산병원에서의 각 항생제에 대한 H. pylori 내성 변화를 보고하는 바이다. 방법: 2004년, 2007년, 2010년에 서울아산병원에서 H. pylori 제균력이 없는 성인 환자에서 분리한 88, 100, 47 균주를 대상으로 amoxicillin, clarithromycin, metronidazole, ciprofloxacin, levofloxacin에 대한 내성률을 조사하였다. 결과: Amoxicillin에 대한 내성률은 2007년에 5.0%, 2010년에 10.6%로 증가하였고, clarithromycin의 경우도 2004년 10.2%, 2007년 11.0%, 2010년 14.8%로 내성률이 증가하였다. 이번 연구에서 metronidazole에 대한 내성률은 차이가 없었으며 tetracycline에 대한 내성 균주는 전혀 발견되지 않았다. Quinolone의 경우 3개년에서 모두 15-17% 정도로 큰 차이가 없었다. 항생제에 내성이 없는 균은 2004년에 56%, 2007년에 62%였고, 2010년에는 43%로 감소하는 경향을 보였으나 통계적 유의성은 없었다(p = 0.066). 다약제 내성률과 표준 1차 치료에 사용되고 있는 amoxicillin과 clarithromycin에 동시 내성률 모두 2007년과 2010년에서 큰 차이가 없었다. 결론: 이번 연구에서도 이전 국내 보고와 마찬가지로 지난 7년 동안 clarithromycin과 amoxicillin에 대한 내성률이 증가함을 보여주었다. 따라서 제균 치료가 지속적으로 유효하기 위해서는 내성균 증가를 억제하기 위한 노력이 필요하다. 또한 현재 보고자마다 각 항생제에 대한 내성률에 차이가 커 표준화된 단일 기준 및 보고 체계와 이를 관리할 수 있는 일원화된 장치 또한 필요할 것으로 생각된다.

Background/AimsPatient compliance and resistance to antibiotics are main factors determining the success of Helicobacter pylori eradication. This study provides basic data to verify the efficacy of currently implemented eradication therapy and reports changes in H. pylori resistance to all antibiotics used at Asan Medical Center, Seoul, Korea from 2004 to 2010.MethodsWe investigated the resistance rates to amoxicillin, clarithromycin, metronidazole, ciprofloxacin, and levofloxacin in 88, 100, and 47 strains isolated from adult patients without H. pylori eradication history in 2004, 2007, and 2010.ResultsThe resistance rate to amoxicillin increased from 5.0% in 2007 to 10.6% in 2010. The resistance rate to clarithromycin increased from 10.2% in 2004 and 11.0% in 2007 to 14.8% in 2010. However, no difference was observed in the resistance rate to metronidazole, and strains resistant to tetracycline were not detected at all in this study. The resistance rates to quinolone lingered at 15-17% for 3 years. The non-resistant strains to antibiotics accounted for 56% of the total in 2004 and 62% in 2007. In contrast, a decreasing tendency was found for those strains in 2010 (43%). No significant differences were shown in the multi-drug resistance rate or the co-resistance rates of amoxicillin and clarithromycin over the 3 years.ConclusionsWe showed increased resistance rates to clarithromycin and amoxicillin over the last 7 years, aligning with the results of previous studies performed domestically. Efforts are needed to inhibit the increase in resistant bacteria to maintain the effectiveness of eradication therapy.

키워드

참고문헌

  1. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007;45:4006-4010. https://doi.org/10.1128/JCM.00740-07
  2. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004;48:4843-4847. https://doi.org/10.1128/AAC.48.12.4843-4847.2004
  3. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12. https://doi.org/10.1111/j.1440-1746.1998.tb00537.x
  4. Chung JW, Lee GH, Han JH, et al. The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology 2011;58:246-250.
  5. Suh SO, Lee DH, Park YS, et al. Difference in Helicobacter pylori eradication rates in patients with peptic ulcer and non-ulcer dyspepsia. Korean J Med 2006;70:505-510.
  6. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2009;54:269-278. https://doi.org/10.4166/kjg.2009.54.5.269
  7. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-913. https://doi.org/10.1016/S0140-6736(11)60020-2
  8. Kim JM, Kim JS, Jung HC, Kim N, Song IS. Antibiotic resistance of Helicobacter pylori isolated from Korean patients in 2003. Korean J Gastroenterol 2004;44:126-135.
  9. Kim JY, Kim N, Kim SJ, et al. Regional difference of antibiotic resistance of Helicobacter pylori strains in Korea. Korean J Gastroenterol 2011;57:221-229. https://doi.org/10.4166/kjg.2011.57.4.221
  10. Chung JW, Lee GH, Jeong JY, et al. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol 2012;27:493-497. https://doi.org/10.1111/j.1440-1746.2011.06874.x
  11. Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J Gastroenterol 2006;47:337-349.
  12. Hwang TJ, Kim N, Kim HB, et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol 2010;44:536-543.
  13. Kim JJ, Reddy R, Lee M, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001;47:459-461. https://doi.org/10.1093/jac/47.4.459
  14. SM J. Comparative analysis of drug misuse after the separation of prescribing and dispensing practice. Korean Institue for Health and Social Welfare Reports 2001:97-103.
  15. Kwon DH, Dore MP, Kim JJ, et al. High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003;47:2169-2178. https://doi.org/10.1128/AAC.47.7.2169-2178.2003
  16. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010;105:65-73. https://doi.org/10.1038/ajg.2009.508

피인용 문헌

  1. Ten-day Sequential TherapyversusBismuth Based Quadruple Therapy as Second Line Treatment forHelicobacter pyloriInfection vol.66, pp.5, 2015, https://doi.org/10.4166/kjg.2015.66.5.261
  2. Current Trends ofHelicobacter pyloriEradication in Korea vol.15, pp.3, 2014, https://doi.org/10.7704/kjhugr.2015.15.3.147
  3. Historical Perspective ofHelicobacter pyloriTreatment in Korea vol.15, pp.4, 2015, https://doi.org/10.7704/kjhugr.2015.15.4.211
  4. Role of Potassium-Competitive Acid Blockers inHelicobacter pyloriEradication vol.17, pp.1, 2014, https://doi.org/10.7704/kjhugr.2017.17.1.20
  5. Antimicrobial Resistance ofHelicobacter pyloriIsolates in Korea vol.18, pp.2, 2014, https://doi.org/10.7704/kjhugr.2018.18.2.82
  6. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial vol.25, pp.46, 2014, https://doi.org/10.3748/wjg.v25.i46.6790
  7. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study vol.9, pp.10, 2020, https://doi.org/10.3390/antibiotics9100646